MARKET

NTRA

NTRA

Natera
NASDAQ

Real-time Quotes | Nasdaq Last Sale

104.06
-0.87
-0.82%
After Hours: 104.07 +0.01 +0.00% 16:10 04/20 EDT
OPEN
104.75
PREV CLOSE
104.93
HIGH
106.04
LOW
101.54
VOLUME
531.45K
TURNOVER
--
52 WEEK HIGH
127.19
52 WEEK LOW
32.80
MARKET CAP
9.12B
P/E (TTM)
-36.9269
1D
5D
1M
3M
1Y
5Y
Prenatal and New-born Genetic Testing Market Share, Size ,Growth, Global Business Prospect, Gross Margin Analysis, Industry Leading Players Update, Development History, and Industry Research Report 2026
Apr 15, 2021 (The Expresswire) -- Global Prenatal and New-born Genetic Testing Market Research Report has In-Depth Collective analysis of different factors...
The Express Wire · 5d ago
Global Prenatal and New-born Genetic Testing Market 2020 Research with COVID-19 Impact Analysis - Segmentation, Regional Outlook and Competition Analysis to 2026
Apr 14, 2021 (CDN Newswire via Comtex) -- Global Prenatal and New-born Genetic Testing Market Growth (Status and Outlook) 2020-2026 identifies the current...
CDN Newswire · 5d ago
Carrier Screening Market Business Scenario Analysis By Global Industry Size, Share, Demand, Segments and Opportunity Assessment till 2027
Apr 14, 2021 (Market Insight Reports) -- The growth of the market is attributed to the growing emphasis on initial detection of diseases and high risks...
Market Insight Reports · 6d ago
Global Cystic Fibrosis(Mucoviscoidosis)Testing Market Overview 2021: Industry Top Manufactures, Size, Share, Trending Technologies, Development Plans, Business Statistics, Regional Analysis and Growth Forecast to 2025
Apr 14, 2021 (The Expresswire) -- "Final Report will add the analysis of the impact of COVID-19 on this industry." The “Cystic...
The Express Wire · 6d ago
Prenatal Testing Market Demand, Growth, Trend, Business Opportunities, Manufacturers and Research Methodology by 2027
Market Insight Reports · 04/13 15:21
Global Non-Invasive Prenatal Testing (NIPT) market size to reach US$ 8.3 Bn by 2025 at a CAGR of 13.5%
Apr 12, 2021 (AB Digital via COMTEX) -- Non-Invasive Prenatal Testing (NIPT) is booming on account of the high risk of chromosomal abnormalities with...
ABNewswire · 04/12 21:07
Non-invasive Prenatal Testing Market Size, Industry Report by Share, Growth, Key Regions, Segments, Trends, Technology and Forecast till 2028
Apr 12, 2021 (Heraldkeepers) -- The global Non invasive Prenatal Testing market is expected to exceed more than US$ 4.5 Billion by 2024 at a CAGR of 17% in...
Heraldkeepers · 04/12 16:45
Non-Invasive Prenatal Testing Market Size, Share, Top Key Players, Growth, Drivers, Research Methodology and Forecast Till 2027
Apr 09, 2021 (Market Insight Reports) -- Growth in the Non-Invasive Prenatal Testing (NIPT) industry is guided by the high probability of chromosomal...
Market Insight Reports · 04/09 13:13
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of NTRA. Analyze the recent business situations of Natera through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 10 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average NTRA stock price target is 137.11 with a high estimate of 150.00 and a low estimate of 115.00.
EPS
Institutional Holdings
Institutions: 372
Institutional Holdings: 97.53M
% Owned: 111.30%
Shares Outstanding: 87.63M
TypeInstitutionsShares
Increased
107
6.73M
New
70
2.60M
Decreased
98
6.10M
Sold Out
21
595.76K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Medical Equipment, Supplies & Distribution
-0.46%
Healthcare Equipment & Supplies
-0.53%
Key Executives
Chairman/Co-Founder/Director
Matthew Rabinowitz
President/Chief Executive Officer/Director
Steven Chapman
Co-Founder/Chief Technology Officer/Director
Jonathan Sheena
Chief Financial Officer/IR Contact Officer
Michael Brophy
Chief Operating Officer
Robert Schueren
Lead Director/Independent Director
Roelof Botha
Independent Director
Roy Baynes
Independent Director
Monica Bertagnolli
Independent Director
Rowan Chapman
Independent Director
Todd Cozzens
Independent Director
James Healy
Independent Director
Gail Marcus
Independent Director
Herman Rosenman
No Data
About NTRA
Natera, Inc. is a diagnostics company. The Company is engaged in the discovery, development and commercialization of genetic testing services. It offers Panorama Non-Invasive Prenatal Test that screens for chromosomal abnormalities of a fetus with a blood draw from the mother; Horizon Carrier Screening to determine carrier status for a large number of severe genetic diseases that could be passed on to the carrier's children; Spectrum Pre-implantation Genetic Screening and Spectrum Pre-implantation Genetic Diagnosis to analyze chromosomal anomalies or inherited genetic conditions during an in vitro fertilization cycle to select embryos with the probability of becoming healthy children; Anora Products of Conception test to analyze fetal chromosomes to understand the cause of miscarriage, and Non-Invasive Paternity Testing, to determine paternity by analyzing the fragments of fetal deoxyribonucleic acid in a pregnant mother's blood and a blood sample from the alleged father(s).

Webull offers kinds of Natera Inc stock information, including NASDAQ:NTRA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, NTRA stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading NTRA stock methods without spending real money on the virtual paper trading platform.